CTI Analyzes TB Natural History Database
The analysis compared various manifestations between genotypes and to determine if correlations exist between TSC symptoms and the TSC gene mutation.
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announced it recently collaborated with the Tuberous Sclerosis Alliance to analyze a Natural History Database of currently more than 1,700 people with tuberous sclerosis complex (TSC).
The analysis compared various manifestations between genotypes and to determine if correlations exist between TSC symptoms and the TSC gene mutation. CTI believes that patient disease groups are increasingly more important in drug development and research in rare diseases, and is working to advance these kind of collaborations and research efforts.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
